Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015)

Expert Opinion on Therapeutic Patents

Volumn 26, Issue 8, 2016, Pages 917-932

  Seganish, W Michael ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

IL R signaling; inflammation; IRAK4; PF 06650833; serine threonine kinase inhibitor; TLR signaling

Indexed keywords

AMIDOPYRAZOLE DERIVATIVE; AMINOPYRIMIDINE DERIVATIVE; BENZOHETEROCYCLE AMIDE DERIVATIVE; BENZOTHIENYLPYRIMIDINE DERIVATIVE; DIAMINOPYRIDINE AMIDE; INDAZOLE AMIDE DERIVATIVE; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4 INHIBITOR; ISOQUINOLINE; PHOSPHOTRANSFERASE INHIBITOR; PYRAZOLE PYRIMIDINE PHENYL COMPOUND; QUINAZOLINE DERIVATIVE; QUINOLINE; THIAZOLOPYRIMIDINE DERIVATIVE; THIENYLPYRIDINE DERIVATIVE; UNCLASSIFIED DRUG; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; PROTEIN KINASE INHIBITOR;

ARTICLE; DRUG EFFICACY; DRUG STRUCTURE; HUMAN; IC50; NONHUMAN; PATENT; PHASE 1 CLINICAL TRIAL (TOPIC); ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; DRUG DESIGN; DRUG EFFECTS; ENZYMOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOMA; SIGNAL TRANSDUCTION;

ANIMALS; ARTHRITIS, RHEUMATOID; DRUG DESIGN; HUMANS; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOMA; PATENTS AS TOPIC; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84978766819     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1080/13543776.2016.1202926     Document Type: Article

References (88)

1. K.A.Staschke, S.Dong, J.Saba, et al. IRAK4 kinase activity is required for Th17 differentiation and Th17-mediated disease. J Immunol. 2009;183:568–577.
2. K.W.Song, F.X.Talamas, R.T.Suttmann, et al. The kinase activities of interleukin-1 receptor associated kinase (IRAK)-1 and 4 are redundant in the control of inflammatory cytokine expression in human cells. Mol Immunol. 2009;46:1458–1466.
3. E.Pauls, S.K.Nanda, H.Smith, et al. Two phases of inflammatory mediator production defined by the study of IRAK2 and IRAK1 knock-in mice. J Immunol. 2013;191:2717–2730.
4. S.Y.Li, A.Strelow, E.J.Fontana, et al. IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase. Proc Nat Acad Sci U S A. 2002;99:5567–5572.
5. A.A.Brzezinska, J.L.Johnson, D.B.Munafo, et al. Signalling mechanisms for Toll-like receptor-activated neutrophil exocytosis: key roles for interleukin-1-receptor-associated kinase-4 and phosphatidylinositol 3-kinase but not Toll/IL-1 receptor (TIR) domain-containing adaptor inducing IFN-beta (TRIF). Immunology. 2009;127:386–397.
6. S.Akira, K.Takeda Toll-like receptor signalling. Nat Rev Immunol. 2004;4:499–511.
7. N.Suzuki, T.Saito IRAK-4 - a shared NF-kappa B activator in innate and acquired immunity. Trends Immunol. 2006;27:566–572.
8. L.A.J.O’Neill. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev. 2008;226:10–18.• Review of IL-R/TLR signaling.
9. F.Zhou, X.W.He, Y.Iwakura, et al. Arthritis in mice that are deficient in interleukin-1 receptor antagonist is dependent on genetic background. Arthritis Rheum. 2005;52:3731–3738.
10. X.Li. IRAK4 in TLR/IL-1R signaling: possible clinical applications. Eur J Immunol. 2008;38:614–618.
11. L.A.B.Joosten, M.G.Netea. Interleukin-1 receptor-associated kinase 4 links innate immunity to the pathogenesis of rheumatoid arthritis. Arthritis Rheum. 2009;60:1571–1574.
12. G.Ferraccioli, L.Bracci-Laudiero, S.Alivernini, et al. Interleukin-1 beta and interleukin-6 in arthritis animal models: roles in the early phase of transition from acute to chronic inflammation and relevance for human rheumatoid arthritis. Mol Med. 2010;16:552–557.
13. Y.Carrier, H.-L.Ma, H.E.Ramon, et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J Invest Derm. 2011;131:2428–2437.
14. M.Coccia, O.J.Harrison, C.Schiering, et al. IL-1 beta mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4(+) Th17 cells. J Exp Med. 2012;209:1595–1609.
15. Y.Liu, H.Yin, M.Zhao, et al. TLR2 and TLR4 in autoimmune diseases: a comprehensive review. Clin Rev Allergy Immunol. 2013;47:136–147.
16. C.A.Dinarello, A.Simon, J.W.M.van der Meer. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11:633–652.
17. E.H.Choy, A.F.Kavanaugh, S.A.Jones. The problem of choice: current biologic agents and future prospects in RA. Nat Rev Rheumatol. 2013;9:154–163.
18. M.Koziczak-Holbro, A.Littlewood-Evans, B.Poellinger, et al. The critical role of kinase activity of interleukin-1 receptor-associated kinase 4 in animal models of joint inflammation. Arthritis Rheum. 2009;60:1661–1671.
19. C.Picard, A.Puel, M.Bonnet, et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science. 2003;299:2076–2079.• Publication on IRAK4-deficient humans.
20. H.Von Bernuth, C.Picard, Z.Jin, et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Science. 2008;321:691–696.
21. C.Picard, H.von Bernuth, P.Ghandil, et al. Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. Medicine. 2010;89:403–425.
22. G.Frans, L.Moens, R.Schrijvers, et al. PID in disguise: molecular diagnosis of IRAK-4 deficiency in an adult previously misdiagnosed with autosomal dominant hyper IgE syndrome. J Clin Immunol. 2015;35:739–744.
23. V.N.Ngo, R.M.Young, R.Schmitz, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470:115–U33.• Role of MYD88 mutations and cancer.
24. J.P.Powers, S.Y.Li, J.C.Jaen, et al. Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4. Bioorg Med Chem Lett. 2006;16:2842–2845.
25. P.N.Kelly, D.L.Romero, Y.Yang, et al. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy. J Exp Med. 2015;212:2189–2201.•• Peer-reviewed publication of selective IRAK4 inhibitors in multiple disease models.
26. Z.Wang, H.Wesche, T.Stevens, et al. IRAK-4 inhibitors for inflammation. Curr Top Med Chem. 2009;9:724–737.
27. J.HynesJr., S.K.Nair. Advances in the discovery of small-molecule IRAK4 inhibitors. Annu Rep Med Chem. 2014;49:117–133.•• Recent review of IRAK4 small-molecule inhibitors.
28. D.Chaudhary, S.Robinson, D.L.Romero. Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders. J Med Chem. 2015;58:96–110.•• Recent review of IRAK4 biology and small-molecule inhibitors.
29. Z.Wang, D.Sun, S.Johnstone, et al. Discovery of potent, selective, and orally bioavailable inhibitors of interleukin-1 receptor-associated kinase-4. Bioorg Med Chem Lett. 2015;25:5546–5550.
30. S.A.Ares Trading Pyrazolylpyrimidine derivatives as IRAK inhibitors and their preparation. WO2014008992A1. 2014.
31. Aurigene Discovery Technologies Ltd. Preparation of bicyclic heterocycles as inhibitors of IRAK4 and other protein kinases for therapy. WO2013042137A1. 2013.
32. Aurigene Discovery Technologies Ltd. Bicyclic heterocyclyl derivatives as IRAK4 inhibitors and their preparation. WO2015104688A1. 2015.
33. Aurigene Discovery Technologies Ltd. Indazole compounds as IRAK4 inhibitors and their preparation. WO2015104662A1. 2015.
34. Aurigene Discovery Technologies Ltd. Substituted indazole compounds as IRAK4 inhibitors. WO2015193846A1. 2015.
35. Curis press release. [cited 2016Mar12]. Available from: http://investors.curis.com/releasedetail.cfm?releaseid=892180
36. Bayer Pharma. Novel carboxamides, method for the production thereof, pharmaceutical preparations comprising them, and use thereof for producing medicaments. WO2015091426A1. 2015.
37. Biogen Idec MA Inc. Preparation of macrocyclic compounds as IRAK4 inhibitors useful for the treatment of inflammatory diseases. WO2014143672A1. 2014.
38. Biogen MA Inc. Arenoazoles as IRAK4 inhibiting agents and their preparation. WO2016011390A1. 2016.
39. Bristol-Myers Squibb Co. Preparation of triazolylpyridine derivatives for use as kinase inhibitors. WO2013106614A1. 2013.
40. Bristol-Myers Squibb Co. Preparation of heterocyclylpyridine derivatives for use as kinase inhibitors. WO2013106641A1. 2013.
41. Bristol-Myers Squibb Co. Preparation of heterocyclylpyridine derivatives for use as kinase inhibitors. WO2013106612A1. 2013.
42. Bristol-Myers Squibb Co. Substituted pyridinecarboxamide compounds as kinase modulators and their preparation. WO2014074657A1. 2014.
43. Bristol-Myers Squibb Co. Substituted pyridinecarboxamide compounds as kinase modulators and their preparation. WO2014074675A1. 2014.
44. Bristol-Myers Squibb Co. Heteroaryl-substituted nicotinamide compounds as IRAK4 inhibitors and their preparation. WO2015103453A1. 2015.
45. F.Hoffmann-La Roche AG. Pyrazolo[1,5-a]pyrimidine and thieno[3,2-b]pyrimidine derivatives as IRAK4 modulators and their preparation. WO2012007375A1. 2012.
46. Ligand Pharmaceuticals Inc. Preparation of heterocycle amines for treating inflammatory disorders. WO2012068546A1. 2012.
47. Ligand Pharmaceuticals Pipeline. [cited 2016 Mar12]. Available from: http://www.ligand.com/what-we-do/portfolio
48. E.G.Vajda, R.Niecestro, Zhi L, et al. IRAK4 inhibitors display synergistic activity when combined with BTK or PI3K inhibitors in B-cell lymphomas. 2015 AACR Annual Meeting; 2015 Apr 18-22; Abstract #785. Philadelphia (PA): American Association for Cancer Research.
49. E.G.Vajda, T.H.Lin, B.Want et al. Novel small molecule inhibitors of interleukin-1 receptor associated kinase-4 are effective in a preclinical model of arthritis. Presented at the Annual Meeting of the American College of Rheumatology; 2011; Chicago (IL): American College of Rheumatology; No. 836.
50. S.A.Merck Serono Preparation of indazolyl triazole derivatives as IRAK inhibitors. WO2012084704A1. 2012.
51. Merck Patent GmbH. Preparation of pyridazinone-amides derivatives for treating inflammatory disease, autoimmune disorder, cancer or multiple sclerosis. WO2014121931A1. 2014.
52. Merck Patent GmbH. Macrocyclic pyridazinone derivatives as IRAK inhibitors and their preparation. WO2014121942A1. 2014.
53. Merck Sharp & Dohme Corp. Preparation of amidopyrazole inhibitors of interleukin receptor-associated kinases. WO2012129258A1. 2012.
54. Merck Sharp & Dohme Corp. Inhibitors of IRAK4 activity. WO2014058691A1. 2014.
55. Merck Sharp & Dohme Corp. Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (IRAK-4). WO2015006181A1. 2015.
56. W.T.McElroy, Z.Tan, G.Ho, et al. Potent and selective amidopyrazole inhibitors of IRAK4 that are efficacious in a rodent model of inflammation. ACS Med Chem Lett. 2015;6:677–682.
57. Astellas Pharma Inc. Preparation of oxazole-carboxamide compounds as IRAK-4 inhibitors. WO2011043371A1. 2011.
58. Merck Sharp & Dohme Corp. Preparation of pyrimidinyl- or pyridinyl-based compounds as inhibitors of IRAK4 activity for treatment of inflammation, proliferative disorders, and immune-related conditions. WO2014058685A1. 2014.
59. Merck Sharp & Dohme Corp. Preparation of aminopyrimidinones as interleukin receptor-associated kinase inhibitors. WO2013066729A1. 2013.
60. W.T.McElroy, W.M.Seganish, R.J.Herr, et al. Discovery and hit to lead optimization of 2,6-diaminopyrimidine inhibitors of interleukin receptor-associated kinase 4. Bioorg Med Chem Lett. 2015;25:1836–1841.
61. W.M.Seganish, W.T.McElroy, R.J.Herr, et al. Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4. Bioorg Med Chem Lett. 2015;25:3203–3207.
62. W.M.Seganish, T.O.Fischmann, B.Sherborne, et al. Discovery and structure enabled synthesis of 2,6-diaminopyrimidin-4-one IRAK4 inhibitors. ACS Med Chem Lett. 2015;6:942–947.
63. Nimbus Iris, Inc. Preparation of substituted 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidines and analogs as IRAK inhibitors. WO2012097013A1. 2012.
64. Nimbus Iris, Inc. Preparation of thieno[2,3-d]pyrimidine derivatives as IRAK inhibitors. WO2013106535A1. 2013.
65. Z.Wang, J.Liu, A.Sudom, et al. Crystal structures of IRAK-4 kinase in complex with inhibitors: a serine/threonine kinase with tyrosine as a gatekeeper. Structure. 2006;14:1835–1844.• Crystal structure of IRAK4.
66. Nimbus Iris, Inc. Preparation of thienopyrimidine compounds as IRAK inhibitors for treatment of cancer, neurodegenerative disorders, and other disease. WO2014011902A1. 2014.
67. Nimbus Iris, Inc. Preparation of thienopyridine compounds as IRAK inhibitors and therapeutic uses thereof. WO2014011906A2. 2014.
68. Nimbus Iris, Inc. Preparation of furano- and pyrrolo-pyrimidine and pyridine compounds as IRAK inhibitors and therapeutic uses thereof. WO2014011911A2. 2014.
69. Nimbus Iris, Inc. Preparation of thiazolo[5,4-d]pyrimidine derivatives as IRAK kinase inhibitors and uses thereof. WO2015048281A1. 2015.
70. Nimbus Iris, Inc. IRAK Inhibitors and Uses Thereof. WO2015164374A1. 2015.
71. Nimbus press release. [cited 2016 Mar12]. Available from: http://www.nimbustx.com/news-events/press-releases/nimbus-therapeutics-announces-global-license-agreement-genentech
72. L.N.Tumey, D.H.Boschelli, N.Bhagirath, et al. Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4. Bioorg Med Chem Lett. 2014;24:2066–2072.
73. L.N.Tumey, V.Rao, N.Bhagirath, et al. Identification and optimization of a series of indolo[2,3-c]quinoline IRAK4 inhibitors. From Abstracts of Papers, 241st ACS National Meeting & Exposition, Anaheim, CA, 2011 Mar 27-31, MEDI-3.
74. Pfizer Inc. Bicyclic-fused heteroaryl or aryl compounds as IRAK4 inhibitors and their preparation. WO2015150995A1. 2015.•• Patent application publication containing Pfizer’s clinical candidate PF-06650833.
75. K.Lee, C.Allais, C.Ambler, et al. Discovery of clinical candidate PF-06650833: a potent, selective, and efficient inhibitor of IRAK4 from fragment-based drug design. From Abstracts of Papers, 251st ACS National Meeting & Exposition, San Diego, CA; 2016 Mar 13-17, MEDI-261.
76. L.van der Fits, S.Mourits, J.S.A.Voerman, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 2009;182:5836–5845.
77. In their 2014 Annual Report. BMS indicated an IRAK4 inhibitor in phase I trials (www.BMS.com), however in their 2015 Annual Report, no such trial is listed.
78. Information on clinical status and indication has been obtained [cited 2016 Mar17] from www.pfizer.com and clinicaltrials.gov
79. Takeda Pharmaceutical Co. Ltd. Preparation of pyrazole compounds as IRAK-4 inhibitors for the treatment autoimmune disorders and other diseases. WO2015068856A1. 2015.
80. P.Cohen. Protein kinases - the major drug targets of the twenty-first century? Nature Rev Drug Discov. 2002;1:309–315.
81. P.Cohen, D.R.Alessi. Kinase drug discovery - what’s next in the field? ACS Chem Biol. 2012;8:96–104.
82. R.RoskoskiJr. A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacol Res. 2015;100:1–23.
83. S.Uematsu, S.Sato, M.Yamamoto, et al. Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-alpha induction. J Exp Med. 2005;201:915–923.
84. E.Y.Chiang, X.Yu, J.L.Grogan. Immune complex-mediated cell activation from systemic lupus erythematosus and rheumatoid arthritis patients elaborate different requirements for IRAK1/4 kinase activity across human cell types. J Immunol. 2011;186:1279–1288.
85. L.Cushing, W.Stochaj, M.Siegel, et al. Interleukin 1/Toll-like receptor-induced autophosphorylation activates interleukin 1 receptor-associated kinase 4 and controls cytokine induction in a cell type-specific manner. J Biol Chem. 2014;289:10865–10875.
86. J.Sun, N.Li, K.-S.Oh, et al. Comprehensive RNAi-based screening of human and mouse TLR pathways identifies species-specific preferences in signaling protein use. Sci Signal. 2016. doi:10.1126/scisignal.aab2191.
87. R.Fleischmann, J.Kremer, J.Cush, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495–507.
88. M.W.Karaman, S.Herrgard, D.K.Treiber, et al. A quantitative analysis of kinase inhibitor selectivity. Nature Biotechnol. 2008;26:127–132.